drugset / Trial / NCT01521533
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of NOX A12 alone and in combination with a background therapy of bortezomib and dexamethasone (VD) chemotherapy in previously treated patients with multiple myeloma (MM).
Timeline
- Start
- 2012-03
- Primary completion
- 2014-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaptesed pegol | Oligonucleotide (other) | 1 mg/kg | Intravenous |
| Subject | Olaptesed pegol | Oligonucleotide (other) | 2 mg/kg | Intravenous |
| Subject | Olaptesed pegol | Oligonucleotide (other) | 4 mg/kg | Intravenous |